Introduction {#s1}
============

Ovarian cancer is the most lethal gynecologic malignancy, with 21,290 estimated new cases and 14,180 estimated deaths in the United States in 2015. Approximately 1.3% of women will be diagnosed with ovarian cancer during their lifetime ([@bib25]). These cancers commonly present as an adnexal mass with cystic components, but are not associated with specific symptoms. As a result, two-thirds of ovarian cancers are diagnosed at late stage (Stage III or IV), when the 5-year survival is less than 30% ([@bib25])

Complicating the diagnosis of ovarian cancer is the fact that ovarian cysts are common in women of all ages, with a prevalence of 35% and 17% in pre- and post-menopausal women, respectively ([@bib47]). These cysts are frequently benign and found incidentally on routine imaging ([@bib47]). Though malignancy is an unusual cause of the cysts, 30% of the cysts exhibit radiographic features suspicious for malignancy, such as solid areas or mass ([@bib47]). In addition to the anxiety that such findings provoke, many women undergo unnecessary surgery for cysts that are not malignant and may not be responsible for the symptoms they have. For example, only 5% of 570 women in a large ovarian cancer screening randomized trial who underwent surgical evaluation actually had a malignancy ([@bib8]). Similarly in another study of symptomatic women, only 4% of 197 women who had concerning features on transvaginal ultrasound were ultimately diagnosed with ovarian cancer ([@bib20]). Compounding this issue is the fact that surgery for ovarian cysts requires general anesthesia and is associated with significant morbidity, causing complications in 15% of women ([@bib9]). These complications include damage to nerves and ureters, bleeding, infection, and perforation of adjacent viscera. Furthermore, the procedure often results in hormonal and fertility loss (in the case of bilateral oophorectomy) ([@bib9]). Even minimal procedures such as ovarian cystectomy can affect fertility in premenopausal women by decreasing follicular response and oocyte number ([@bib37]; [@bib16]). If a preoperative test could help determine whether the cystic lesion was benign or malignant, unnecessary surgery and its associated complications could be avoided in many patients. This would be particularly helpful for women of reprodutive age who wish to preserve their fertility, as well as women whose medical comorbidities or functional status makes anesthesia and surgery hazardous.

Ovarian cysts and tumors are classified as non-neoplastic, benign, borderline, or malignant based on microscopic examination after surgical removal ([Figure 1](#fig1){ref-type="fig"}). Non-neoplastic cysts are by far the most common class of ovarian cysts. They are frequently found in pre-menopausal women, arising when an egg is not released properly from either the follicle or corpus luteum and usually resolve spontaneously within several months ([@bib13]). Benign cystic tumors, such as cystadenomas and cystadenofibromas, rarely progress to malignancy ([@bib12]; [@bib35]). No genetic alterations have yet been identified in either non-neoplastic cysts or in benign cystic tumors ([@bib12]). Neither of these cyst types requires surgery unless they are symptomatic or large ([@bib35]). These cysts can be easily sampled with ultrasound-guided fine-needle aspiration within minutes in an outpatient setting without the need for anesthesia ([@bib17]).10.7554/eLife.15175.003Figure 1.Schematic showing classes of ovarian cysts and the diagnostic potential of the cyst fluid.Ovarian cysts and tumors are currently classified according to microscopic evaluation after surgical removal. The majority of ovarian cysts are non-neoplastic (often \'functional\' in premenopausal women). Ovarian tumors with combined cystic and solid components are either benign tumors, borderline tumors, or malignant cancers (type I or II). Only cysts associated with borderline tumors and cancers require surgical excision. We show here that the DNA purified from cyst fluid can be analyzed for somatic mutations commonly found in their associated tumors. The type of mutation detected not only could indicate the type of tumor present but also could potentially inform management.**DOI:** [http://dx.doi.org/10.7554/eLife.15175.003](10.7554/eLife.15175.003)

At the other end of the spectrum are epithelial ovarian cancers, which are potentially lethal and unequivocally require surgery. A dualistic model has been proposed to classify these neoplasms ([@bib32]). Type I tumors are composed of low-grade serous, low-grade endometrioid, clear cell, and mucinous carcinomas. They are generally indolent, frequently diagnosed at early stage (Stage I or II), and develop from well-established precursor lesions (\'borderline\' or \'atypical proliferative\' tumors, as described below) ([@bib33]). Type I cancers commonly exhibit mutations in *KRAS, BRAF, CTNNB1, PIK3CA, PTEN, ARID1A*, or *PPP2R1A* ([@bib32]). In contrast, type II tumors are generally high-grade serous carcinomas. They are highly aggressive, most often diagnosed in late stage (Stage III or IV), and have suggested origins from the distal fallopian tube ([@bib34]). Type II cancers are the most clinically important group of ovarian cancers, comprising 75% of all ovarian carcinomas and responsible for 90% of ovarian cancer deaths ([@bib33]). They almost always harbor *TP53* mutations ([@bib10]). Also unlike type I cancers, which are relatively chemo-resistant and more often treated only with surgical excision, type II cancers respond to conventional chemotherapy, particularly after maximal debulking to reduce tumor burden ([@bib7]; [@bib49]).

\'Borderline\' or \'atypical proliferative\' tumors lie in the middle of this spectrum, between the malignant cancers and the generally harmless non-neoplastic or benign lesions. They are distinguished from carcinomas by the absence of stromal invasion and are precursors of type I cancers. In light of their potential for malignancy, the standard of care for borderline tumors is surgical excision. Following surgery, the prognosis is excellent compared to ovarian cancers, with 10-year survival rates over 94% ([@bib51]). A minor but significant portion of borderline tumors recur after surgery, however, and a subset of the recurrences are found to have advanced to type I cancers ([@bib52]). This progression is consistent with molecular findings: serous borderline tumors typically exhibit mutations in *BRAF* or *KRAS*, like their malignant counterparts (low-grade serous carcinoma) ([@bib39]; [@bib26]). The presence of a *BRAF* mutation in a borderline tumor is associated with better prognosis and a low probability of progression to carcinoma ([@bib21]). In contrast, *KRAS* mutations are associated with the progression to type I cancers ([@bib55]).

The examination of fluids from pancreatic, renal, and thyroid cysts is routinely used in clinical management ([@bib19]; [@bib36]; [@bib59]). The fluids have historically been studied by cytology to identify malignant cysts. Ovarian cysts share many features with these other types of cysts, in that they are common, often diagnosed incidentally, and are nearly always benign. However, aspiration of ovarian cyst fluid for cytology is not standard-of-care. From a historical perspective, the difference in diagnostic management partly lies in the fact that cytology has not proven to be very informative for ovarian cysts, particularly for distinguishing benign vs. borderline tumors ([@bib40]; [@bib38]). There have also been concerns raised about the safety of ovarian cyst aspiration (see Discussion), and these concerns have not often been raised for other types of cysts.

More recently, genetic analysis of specific types of cyst fluids has been considered as an aid to cytology, given that conventional cytology often has limited sensitivity and specificity ([@bib61]). Based on the emerging success of the molecular genetic evaluation of other types of cysts, we reasoned that a similar approach could be applied to ovarian cysts. Evaluation of DNA from cells and cell fragments shed into the cyst fluid would presumably allow the identification of tumor-specific mutations. Unlike other, conventional markers of neoplasia such as CA-125, cancer gene mutations are exquisitely specific indicators of a neoplastic lesion ([@bib58]). Moreover, the type of mutation can in some cases indicate the type of neoplastic lesion present ([@bib60]). Yamada et al. have demonstrated that mutations can be detected in the cystic fluid of ovarian tumors by querying exons 4 to 9 of *TP53*, achieving sensitivities of 12.5% and 10%, for borderline and malignant tumors, respectively ([@bib62]). Recently developed, extremely sensitive methods for mutation detection, capable of identifying one mutant template allele among thousands of normal templates in a panel of genes, could potentially increase this sensitivity ([@bib28]; [@bib43]; [@bib44]). In this study, we have applied one of these technologies to assess mutations in ovarian cyst fluids and to inform the development of tests that could eventually be applied to patients.

Results {#s2}
=======

Characteristics of the tumors and cyst fluid samples {#s2-1}
----------------------------------------------------

DNA was isolated from surgically excised ovarian cysts of 77 women. Ten of them had non-neoplastic cysts, 12 had benign tumors, 24 had borderline tumors, and 31 had cancers (13 Type I and 18 Type II). Age, histopathologic diagnosis, stage, and other clinical information are provided in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. The median amount of DNA recovered from the cysts was 222 ng (interquartile range (IQR) of 53 to 3120 ng) ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). There was no significant difference in the amounts of DNA between borderline tumors and type I or type II cancers. However, the borderline tumors and cancers contained significantly more DNA than the non-neoplastic cysts or benign tumors (4453 ± 6428 ng vs. 62 ± 64 ng; p\<0.001, Wilcoxon rank-sum test).

A multiplex PCR-based assay to identify tumor-specific mutations in cyst fluid samples {#s2-2}
--------------------------------------------------------------------------------------

We designed a multiplex PCR-based assay that could simultaneously assess the regions of 17 genes frequently mutated in ovarian tumors. The amount of DNA shed from neoplastic cells was expected to be a minor fraction of the total DNA in the cyst fluid, with most DNA emanating from normal cells. We therefore used a sensitive detection method, called Safe-SeqS (Safe-Sequencing System), to identify mutations in cyst fluid samples ([@bib28]). In brief, primers were designed to amplify 133 regions, covering 9054 distinct nucleotide positions within the 17 genes of interest ([Supplementary file 3](#SD3-data){ref-type="supplementary-material"}). Three multiplex PCR reactions, each containing non-overlapping amplicons, were then performed on each sample. One primer in each pair included a unique identifier (UID) for each template molecule, thereby drastically minimizing the error rates associated with PCR and sequencing, as described previously ([@bib28]). Under the conditions used in the current experiments, mutations present in \>0.1% of template molecules could generally be reliably determined ([@bib28]; [@bib29]; [@bib6]). We could not perform sequencing on five cysts (four non-neoplastic cysts and one cyst associated with a borderline tumor) because there was insufficient DNA (\<3 ng recovered), and these were scored as uninterpretable. When this assay was applied to cyst fluid samples with sufficient DNA, no mutations were identified in the 18 cysts obtained from patients with simple cysts (n = 6) or benign tumors (n = 12) ([Table 1](#tbl1){ref-type="table"}). This was in stark contrast to the fluids obtained from the 18 patients with type II cancers, all of which were found to contain a mutation ([Table 1](#tbl1){ref-type="table"}). Ten (77%) of the 13 cyst fluids from patients with type I cancers and 19 (83%) of the 23 cyst fluids from patients with borderline tumors contained at least one detectable mutation. When categorized by the need for surgery (i.e., presence of a borderline tumor or a type I or type II cancer), the sensitivity of this assay was 87% (47 of 54 cysts; 95% confidence interval of 75% to 95%) and its specificity was 100% (95% confidence interval of 74% to 100%; [Table 1](#tbl1){ref-type="table"}).10.7554/eLife.15175.004Table 1.Detection of tumor-specific mutations in cyst fluid. The fraction of samples detected and the median fraction of mutant alleles are indicated, grouped by cyst type, cancer stage, and the need for surgery.**DOI:** [http://dx.doi.org/10.7554/eLife.15175.004](10.7554/eLife.15175.004)Fraction of samples detected (95% confidence interval)Median fraction of mutant alleles (IQR)Total \# of samples*Type*Non-neoplastic0% (0--46%)0% (0--0%)6Benign tumor0% (0--26%)0% (0--0%)12Borderline tumor83% (61--95%)2.4% (1.5--10.8%)23Type I cancer77% (46--95%)7.8% (3.3--28.7%)13Type II cancer100% (81--100%)60.3% (31.3--70.8%)18*Cancer stage*Early (I and II)82% (48--97%)7.4% (3.0--30.9%)11Late (III and IV)95% (75--100%)51.2% (30.2--69.5%)20*Cysts requiring surgery*No0% (0--26%)0% (0--0%)18Yes87% (75--95%)12.6% (2.7--40.2%)54

Ovarian cancers are generally detected only late in the course of disease, perhaps explaining the poor prognosis of patients. Accordingly, only 11 of the 31 cysts associated with cancers in our study had early (Stage I or II) disease ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). As expected, most of these were type I carcinomas (n = 8). Nevertheless, it was encouraging that mutant DNA could be detected in nine (82%) of these 11 patients ([Table 1](#tbl1){ref-type="table"}). Mutations could be detected in 95% of the 20 patients with Stage III or IV cancers ([Table 1](#tbl1){ref-type="table"}).

A variety of control experiments were performed to confirm the integrity of these results. One informative positive control was provided by the analysis of DNA from the tumors, using the identical method used to analyze DNA from the cyst fluids. Fifty-three of the 55 borderline and malignant cases had tumors available for this purpose. Every mutation identified in a tumor was found in its cyst fluid, and vice versa. As expected, the mutant allele frequencies in the tumors were often, but not always, higher than in the cyst fluids ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). As another positive control, we used an independent PCR and sequencing reaction to confirm each of the cyst fluid mutations listed in [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}. This validated not only the presence of a mutation, but also confirmed its fractional representation. The median relative difference between the fractions of mutant alleles in replicate experiments was 7.0% (IQR of 3.5% to 8.9%). Finally, four patients were found to have two independent mutations ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). For example, the cyst fluid of patient OVCYST 081, who had a high-grade endometrioid carcinoma, harbored a missense mutation (R280K) in *TP53* plus an in-frame deletion of *PIK3R1* at codons 458 and 459. The *TP53* mutation was found in 3.0% of alleles while the *PIK3R1* mutation was found in 3.7% of the alleles analyzed. Similar mutant allele frequencies among completely different mutations in the cyst fluid of three other patients provided further indicators of reproducibility. All genetic assays were performed in a blinded manner, with the operator unaware of the diagnoses of the patients from whom the cyst fluids were obtained.

In addition to DNA from normal individuals used as controls, additional negative controls were provided by the simple cysts and benign tumors. Using the identical assay, none of the DNA from their cyst fluids contained detectable mutations. A final control was provided by the borderline and malignant tumors themselves. In general, only one or two of the 9054 base-pairs (bp) queried were mutated in any one *tumor* ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). The other \~9000 bp could then be independently queried in the corresponding *cyst* fluid, and none of these positions were found to be mutated.

Relationship between the type of tumor present and the type of mutation found in the associated cyst fluid sample {#s2-3}
-----------------------------------------------------------------------------------------------------------------

The mutant allele fractions in the cyst fluids tended to be higher in the type II cancers (median of 60.3%) than the type I cancers (median of 7.8%) or borderline tumors (median of 2.4%), though there was considerable overlap ([Table 1](#tbl1){ref-type="table"}; [Figure 2A](#fig2){ref-type="fig"}). With respect to stage, the DNA from cyst fluids of late-stage cancers had higher median mutant allele fractions (51.2%) than those of early-stage cancers (7.4%) or borderline tumors (2.4%), but with considerable overlap ([Table 1](#tbl1){ref-type="table"}; [Figure 2B](#fig2){ref-type="fig"}).10.7554/eLife.15175.005Figure 2.Mutant allele fractions.(**A**) Classification by tumor type. No mutations were found in the DNA of non-neoplastic or benign cysts. Of the cysts that required surgery, the median mutant allele fraction was higher in the cyst fluids associated with type II cancer (60.3%) than type I (7.8%) or borderline tumors (2.4%). (**B**) Classification by tumor stage. The DNA from cyst fluids of late-stage cancers had a higher median mutant allele fraction (51.2%) than those of early-stage cancers (7.4%) or borderline tumors (2.4%). Percent mutant allele is depicted on a logarithmic scale. Horizontal bars depict median and IQR.**DOI:** [http://dx.doi.org/10.7554/eLife.15175.005](10.7554/eLife.15175.005)

On the other hand, the type of mutation varied considerably among these cysts ([Figure 3](#fig3){ref-type="fig"}). In type I tumors, the genes mutated were *BRAF* (n = 1), *KRAS* (n = 5), *NRAS* (n = 1), *PIK3R1* (n = 1), *PPP2R1A* (n = 1), *PTEN* (n = 1), or *TP53* (n = 3). Two distinct mutations were found per sample in three type I cancers. The *BRAF* mutation (V600_S605 \> D) was unusual that it resulted from an in-frame deletion/insertion rather than the base substitution (V600E) characteristic of the vast majority of *BRAF* mutations reported in the literature. This mutation has been observed in a papillary thyroid cancer and a cutaneous melanoma ([@bib14]; [@bib3]). The deletion results in loss of a phosphorylation site in the activation loop of BRAF, while the insertion of an aspartic acid has been suggested to increase BRAF kinase activity by mimicking an activating phosphorylation ([@bib15]). In contrast, all but one type II cancers (94% of 18) had mutations in *TP53*; the only exception was OVCYST 073, a high-grade endometrioid carcinoma. The borderline tumors were distinguished by yet a different pattern from that of the either type I or type II cancers. Of the 19 mutations in borderline tumors, 12 (63%) were *BRAF* V600E, never observed in type I or type II cancers, and the remainder were at *KRAS* codon 12 or 61 ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}).10.7554/eLife.15175.006Figure 3.Mutated genes found in the cyst fluid samples.Yellow boxes represent mutations with mutant allele frequency (MAF) between 0.1% and 1%; orange boxes represent mutations with MAF between 1 and 10%; red boxes represent mutations with MAF greater than 10% (\* indicates patients with insufficient DNA for analysis; \*\* indicates patients with two detected mutations).**DOI:** [http://dx.doi.org/10.7554/eLife.15175.006](10.7554/eLife.15175.006)

Markers associated with the need for surgery {#s2-4}
--------------------------------------------

A multivariate analysis was used to identify the most informative molecular features of cyst fluids and to compare them to the commonly used serum biomarkers for ovarian cancer, HE4 (human epididymis protein 4) and CA-125 ([@bib4]; [@bib23]) ([Table 2](#tbl2){ref-type="table"}). We defined \'informative\' as indicating a need for surgery (i.e., borderline tumors or type I or II cancers). The amount of DNA in cyst fluids was generally, but not significantly, higher in the cysts requiring surgery (p=0.69, [Table 2](#tbl2){ref-type="table"}), though there were many cysts not requiring surgery that had higher DNA levels than cysts requiring surgery ([Figure 4A](#fig4){ref-type="fig"}). Similarly, the serum CA-125 levels were significantly higher in cysts requiring surgery (p=0.01, [Table 2](#tbl2){ref-type="table"}), but there were many cysts not requiring surgery that had higher levels than those requiring surgery ([Figure 4B](#fig4){ref-type="fig"}). Serum HE4 levels were not correlated with cyst type (p=0.92, [Table 2](#tbl2){ref-type="table"}; [Figure 4C](#fig4){ref-type="fig"}). On the other hand, the presence of a mutation was highly informative for the presence of a cyst requiring surgery in the multivariate analysis, as no mutations were found in cysts not requiring surgery (p\<0.001, [Table 2](#tbl2){ref-type="table"}).10.7554/eLife.15175.007Table 2.Multivariate analysis for markers associated with need for surgery. The presence of a mutation, cyst DNA amount, and common serum biomarkers for ovarian cancer were analyzed for association with cysts that require surgical removal (Firth's penalized likelihood logistic regression).**DOI:** [http://dx.doi.org/10.7554/eLife.15175.007](10.7554/eLife.15175.007)Criteriap valueMutation present\<0.001Serum CA-125 elevated0.01HE4 elevated0.92Cyst DNA amount0.6910.7554/eLife.15175.008Figure 4.Markers associated with the need for surgery.Cyst DNA amount and levels of commonly used ovarian cancer serum biomarkers are plotted according to the cyst type and need for surgery. (**A**) The amounts of DNA in cyst fluids was generally higher in cysts requiring surgery (blue) than those that do not (red), but no significant correlation was found (p=0.69). (**B**) CA-125 levels was significantly higher in cysts that required surgery than those that do not (p=0.01). (**C**) Serum HE4 levels was not correlated with the need for surgery (p=0.92). All values are depicted on a logarithmic scale. P-values were calculated using Firth's penalized likelihood logistic regression in a multivariate model (See Materials and methods).**DOI:** [http://dx.doi.org/10.7554/eLife.15175.008](10.7554/eLife.15175.008)

Discussion {#s3}
==========

Ovarian cancer is the most lethal gynecologic cancer in women. However screening is not recommended by the U.S. Preventive Services Task Force using current diagnostic approaches, which too frequently lead to "important harms, including major surgical interventions in women who do not have cancer" ([@bib41]). Our study was driven by the underlying principle that clonal cancer driver gene mutations are causative agents of neoplasia and absent in non-neoplastic conditions ([@bib58]). We have demonstrated here that driver mutations in ovarian tumors are also present in their associated cyst fluids. Moreover, the mutant allele frequencies in the cyst fluids are relatively high (median 12.6%, IQR of 2.7% to 40.2%), facilitating their detection. There were no mutations detected in the cyst fluids that were not also present in the tumors, and vice versa. Also importantly, no mutation was identified in non-neoplastic cysts or cysts associated with benign tumors. Overall, mutations were detected in a major fraction (87%) of cysts requiring surgery but not in any cyst that did not require surgery ([Table 1](#tbl1){ref-type="table"}).

Although most (87%) of the 54 cysts requiring surgery had detectable mutations in their fluidic compartment, 7 did not. All of these seven cysts occurred in borderline tumors or type I cancers, while mutations were always (100%) detectable in type II cancers ([Table 1](#tbl1){ref-type="table"}). There are two potential explanations for our failure to detect mutations in these seven cysts. First, it is possible that the mutant DNA concentration in these cysts was below the level of technical sensitivity of our assay (\~0.1% mutant allele fraction). We excluded this possibility by evaluating the tumors themselves: no mutations were detected in any of the tumors from these 7 patients. The second, and therefore more likely explanation, is that our panel of 133 amplicons, containing regions of 17 genes, was not adequate to capture the mutations that were present. Unlike type II cancers, which nearly always contain *TP53* mutations (94% of the type II cancers we studied, for example), the genomic landscapes of type I cancers and borderline tumors are more heterogeneous and not as well studied ([@bib32]). Further genetic evaluation of these tumors should facilitate the incorporation of additional amplicons in the panel to reach higher sensitivities. Nevertheless, the 100% sensitivity for type II cancers in our study is highly encouraging, given that these cancers account for over 90% of ovarian cancer deaths.

One limitation of our study is the number of patients evaluated. Though excision of ovarian cysts is one of the most commonly performed surgical procedures, banking of cyst fluids is not common, even in academic centers. Thus, we only had relatively small numbers (n = 22) of non-neoplastic cysts and benign tumors available for study. Even so, the differences in genetic alterations among the various cyst types were striking ([Table 1](#tbl1){ref-type="table"}). Our study will hopefully stimulate collection and analyses of ovarian cyst fluids that will be able to establish smaller confidence limits around the sensitivities and specificities reported in the current study.

A potential clinical limitation of our approach is the concern by gynecologists that needle puncture of a malignant ovarian cyst leads to seeding of the peritoneum. This concern is based on inconclusive evidence about the dangers of cyst rupture during surgery and is, at best, controversial. A study of 235 patients who had pre-operative ovarian cyst aspirates reported no recurrence in all 7 malignant cases with a mean follow-up of two years ([@bib42]). Furthermore, a meta-analysis found no difference in progression-free survival for 2382 early-stage ovarian cancer patients who had experienced intraoperative cyst rupture vs. no rupture ([@bib27]). We acknowledge that, under current recommendations, a surgical spill could upstage a localized tumor (i.e. stage 1A to IC) and subject the patient to chemotherapy with its associated morbidity. However, the idea that malignant cysts might shed cancer cells if needle-punctured seems incongruent with the widespread practice of laparoscopic removal of ovarian cysts ([@bib24]). Laparoscopic removal of a cyst carries a significant risk of cyst rupture, conceivably higher than when a tiny needle is inserted under ultrasound-guidance ([@bib22]). Finally, malignant pancreatic cysts might be viewed to be as dangerous as malignant ovarian cysts ([@bib25]), yet the standard-of-care for pancreatic cysts involves repeated sampling of cyst fluid through endoscopic ultrasound over many years ([@bib11]; [@bib18]). Though pancreatic cysts and ovarian cysts lie in different anatomical compartments, it is encouraging that aspiration of pancreatic cysts is not associated with an increased risk of disease recurrence or mortality in patients with pancreatic cancer ([@bib5]; [@bib45]; [@bib31]; [@bib46]). Recent advancements in methods of plugging biopsy tracts to prevent tumor cell dissemination, as well as the increased use of intraperitoneal chemotherapy, further lessen the concern of tumor cell dissemination following ovarian cyst aspiration ([@bib1]; [@bib54]; [@bib56]; [@bib53]). On the basis of these observations and recent developments, we believe that ultrasound-guided aspiration of ovarian cyst fluids would likely be a safe and well-tolerated procedure.

As noted in the introduction, as many as twenty patients with benign ovarian cyst lesions undergo surgery for each case of ovarian cancer found ([@bib8]). In addition to the psychological impact a potential diagnosis of cancer has on patients, surgery for benign lesions entails considerable cost and morbidity. With the ever increasing sensitivity and use of imaging modalities, the number of patients with incidentally found ovarian cysts is expected to rise. This urgently calls for a diagnostic method that reliably differentiates between the harmless cysts that can be managed expectantly and malignant cysts that require surgical resection. OVA-1 is the only FDA-cleared test to date that aims to distinguish benign versus malignant adenxal mass. It measures levels of five serum markers (CA-125, β-2 microglobulin, apolipoprotein A1, Prealbumin, and transferrin) and is used to stratify patients who should consult a gynecologic oncologist rather than a general gynecologist for surgery. However the test has a specificity of 43% for ovarian cancer, which is even lower than that of CA-125 alone ([@bib57]). While the test might encourage patients with suspected ovarian cancer to seek specialized care, it would not decrease the number of unnecessary surgeries for women with benign adnexal masses.

This study was driven by the need for a biomarker that would help distinguish malignant ovarian tumors from benign lesions and thereby reduce the number of unnecessary surgeries. Such distinction is often difficult based on symptoms and conventional diagnostic criteria. For example, in a large study of 48,053 asymptomatic postmenopausal women who underwent ultrasound examination by skilled sonographers, 8 (17%) of the 47 ovarian cancers that were identified occurred in women with persistently *normal* sonographic findings ([@bib50]). All eight cases were type II cancers, highlighting the potential utility of an additional assay to detect this highly lethal and aggressive type of ovarian cancer. On the other hand, of the 4367 women with *abnormal* sonographic findings, less than 1% of cases proved to have malignancy upon surgery. Furthermore, of the 32 women with borderline or Type I cancers diagnosed, 22 (69%) had a serum CA-125 level within the clinically accepted normal range (≤35 units/mL). In our study, 18 of 18 (100%) type II cancers were detectable by virtue of the mutations found in cyst fluid DNA while none of the 18 benign or non-neoplastic cyst fluid contained such mutations. It is also important to note that the readout of our assay is quantitative and not dependent on the skill level of the reader (in contrast to sonography). Finally, the procedure can be performed minimally invasively in an outpatient setting. The goal of our test is not to replace clinical, radiologic, or sonographic evaluation but to augment them with molecular genetic markers.

Our study, though only proof-of-principle, illustrates one route to improve the management of patients with ovarian cysts. Genetic analysis is not the only such route; proteomics could also provide clues to the correct diagnosis ([@bib2]; [@bib30]). One can easily imagine how such additional information could be used to inform clinical practice in conjunction with current diagnostic approaches. For example, if a cyst contained low amounts of DNA, no detectable mutations, and if the patient had low CA-125 levels, our data suggest that it is very unlikely to be a borderline tumor or malignant lesion. Either no surgery, or laparoscopic rather than open surgery, could be recommended for that patient, even if there were some solid component upon imaging. The option to avoid surgery would be particularly valuable for pre-menopausal women who generally have a low risk of ovarian cancer and might wish to preserve their fertility, as well as patients who are poor surgical candidates. However, our assay in its current format cannot completely rule out malignancy because a fraction of early-stage cancer patients did not have detectable mutations in their cysts. Therefore, patients whose clinical and functional status allows them to undergo surgery and anesthesia might still choose to have a surgical procedure. On the other hand, a minimally invasive test that provides additional, orthogonal information to patients and surgeons could inform their decision about the advisability of surgery.

Our data suggest that a cyst without any solid component upon imaging, and thereby unlikely via conventional criteria to be malignant, should be removed promptly if the cyst fluid contained a *TP53* mutation. Radical, rather than conservative, surgery might be appropriate due to the high likelihood of an aggressive type II cancer. In contrast, if a *BRAF* mutation is identified, the lesion is presumably a borderline or low-grade tumor; thus conservative rather than radical surgery might be sufficient. Furthermore, given that certain types of ovarian cancers (type II) tend to respond well to chemotherapy while others (type I) are relatively chemo-resistant, knowing the type of cancer present prior to surgery based on the mutation profile could help guide decisions regarding the use of neoadjuvant chemotherapy. Validation of the current data in a large, prospective trial will be required before the approach can be seriously considered for clinical implementation in a non-research setting.

Materials and methods {#s4}
=====================

Patient samples {#s4-1}
---------------

Cyst fluids were collected prospectively from women presenting with a suspected ovarian tumor. Patients were diagnosed by transvaginal sonography or computed tomography and admitted for surgical removal of the cyst due to suspicious imaging findings by gynecologic oncology surgeons at Sahlgrenska University Hospital, Gothenburg, Sweden. The study was approved by the ethical board of Gothenburg University and patients provided written consent. According to the approved protocol, 15 to 20 mL of ovarian cyst fluid was collected after removal of the cyst from the abdomen. All samples were immediately put in 4°C for 15--30 min, centrifuged for 10 min at 500 g, and aliquoted into Eppendorf tubes. The fluids were transferred to −80°C, within 30--60 min after collection. All histology was reviewed by board-certified pathologists ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). Ten, 12, 24, and 31 cyst fluid samples from patients with non-neoplastic cysts, benign tumors, borderline tumors, and malignant ovarian cancers, respectively, were assayed in this study.

Plasma HE4 concentrations were determined using a commercial HE4 EIA assay (Fujirebio Diagnostics, PA, USA) and plasma CA-125 levels were measured using the Architect CA 125 II (Abbott Diagnostics, IL, USA). DNA was purified from tumor tissue (either freshly-frozen, or formalin-fixed and paraffin-embedded) after microdissection to remove neoplastic components. DNA was purified from tumors and from 1 mL of each cyst fluid sample using an AllPrep DNA kit (Qiagen, Germany) according to the manufacturer's instructions. Purified DNA from all samples was quantified as previously described ([@bib48]).

Statistical analysis {#s4-2}
--------------------

A Wilcoxon rank-sum test was used to compare the amount of DNA in the cancers and borderline tumors with the amount of DNA in the simple cysts and benign tumors. The fraction of samples detected by tumor-specific mutations in the cyst fluid, as well as their 95% confidence intervals, was calculated for each tumor type ([Table 1](#tbl1){ref-type="table"}). When the presence of a mutation in the cyst fluid was used to predict the need for surgery, the sensitivity and specificity of the assay, as well as the 95% confidence intervals, were calculated. Firth's penalized likelihood logistic regression was used to quantify the association between molecular features of cyst fluids and the need for surgery ([Table 2](#tbl2){ref-type="table"}) in a multivariate model. The model predictors included the presence of mutation, log10(ng) of cyst DNA and indicators for normal CA-125 and HE4 values. Normal CA-125 values were defined as \<35 U/mL and normal HE4 values were defined as \<92 pmol/L and \<121 pmol/L for pre- and post-menopausal women, respectively, according to the cutoffs used at the Sahlgrenska University Hospital. Statistical analyses were performed using the R statistical package (version 3.1.2). Unless noted otherwise, all patient-related values are reported as means ± SD.

Mutation detection and analysis {#s4-3}
-------------------------------

DNA from either cyst fluids or tumors was used for multiplex PCR, as previously described ([@bib28]) with the exceptions noted below. One-hundred-and-thirty-three primer pairs were designed to amplify 110 to 142 bp segments containing regions of interest from the following 17 genes: *AKT1, APC, BRAF, CDKN2A, CTNNB1, EGFR, FBXW7, FGFR2, KRAS, MAPK1, NRAS, PIK3CA, PIK3R1, POLE, PPP2R1A, PTEN*, and *TP53*. Primer sequences are listed in [Supplementary file 3](#SD3-data){ref-type="supplementary-material"}. These primers were used to amplify DNA in 25 μL reactions as previously described except that 15 cycles were used for the inial amplification ([@bib28]). For each sample, three multiplex reactions, each containing non-overlapping amplicons, were performed. Reactions were purified with AMPure XP beads (Beckman Coulter, PA, USA) and eluted in 100 μL of Buffer EB (Qiagen). A fraction (0.25 μL) of purified PCR products were then amplified in a second round of PCR, as described ([@bib28]). The PCR products were purified with AMPure and sequenced on an Illumina MiSeq instrument.

To better distinguish genuine mutations in the samples from artifactual variants arising from sequencing and sample preparation steps, we used Safe-SeqS, an error-reduction technology for detection of low frequency mutations as described ([@bib28]). High quality sequence reads were selected based on quality scores, which were generated by the sequencing instrument to indicate the probability a base was called in error. The minimum quality score requirements were 15 (base call accuracy of 97%) and 20 (base call accuracy of 99%) for each of the fourteen UID bases and mutant base(s), respectively. The template-specific portion of the reads was matched to reference sequences using custom scripts written in SQL and C\#. Reads from a common template molecule were then grouped based on the unique identifier sequences (UIDs) that were incorporated as molecular barcodes. Artifactual mutations introduced during the sample preparation or sequencing steps were reduced by requiring a mutation to be present in \>90% of reads in each UID family (i.e., to be scored as a \'supermutant\'). Only mutations with mutant allele frequency (MAF) above 0.1%, the limit of sensitivity of the assay performed, were considered as positive. Silent or intronic mutations (other than those in the canonical splice sites) were not considered to be mutations because their significance is unknown. In addition, DNA from the peripheral blood lymphocytes of healthy individuals was used as a control to identify potential false positive mutations (see main text). Only supermutants in samples with frequencies far exceeding their frequencies in control DNA samples (i.e., \> mean + 5 standard deviations) were scored as positive. The original sequencing data on all mutations listed in [Supplementary file 2](#SD2-data){ref-type="supplementary-material"} were manually reviewed to confirm that the mutations were correctly called by the Illumina software. Moreover, each of these mutations was validated by an independent PCR and sequencing reaction.
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Decision letter
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Canada

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Diagnostic Potential of Tumor DNA from Ovarian Cyst Fluid\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor (Eduardo Franco) and Charles Sawyers as the Senior Editor. Three reviewers were consulted, including Alex Shu-Wing Ng and Michelle Davis who agreed to reveal their identities.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Wang et al. analyzed whether known mutations in ovarian cancer could be found in the patients\' ovarian cyst fluid specimens through a highly sensitive sequencing assay. The authors indeed identified specific mutations in borderline tumors, type I+II cancers while no mutations were found in benign or non-neoplastic cystic lesions. The authors conclude that mutant DNA identified in ovarian cyst fluid may guide the diagnostic and therapeutic management of patients with ovarian cysts.

Essential revisions:

Issues related to the study\'s methodology and interpretation:

1\) Methodology needs more details: (i) which tools were used for sequence data alignment? (ii) which tools and what parameters were used for variant calling (including the minimum read count requirement or the minimum variant allele frequency)? (iii) what sequencing depth was achieved per sample? (iv) what was the sequence read quality cut-off used? (v) were variants manually reviewed? (vi) were variant calls limited to missense and nonsense mutations or were no silent mutations observed?

2\) Subsection "A multiplex PCR-based assay to identify tumor-specific mutations in cyst fluid samples": The 5 samples without sufficient DNA should not be included in the analysis. These cases should be excluded instead of included as negative because in clinical practice this would be uninterpretable and thus represents a failure of the technique. While this is small, 5/77 (6.5%) it still should be reported in this manner as low DNA alone, as the authors indicated, is not indicative of a benign cyst and 1 borderline tumor would have been missed with this technique.

3\) In [Figure 2](#fig2){ref-type="fig"} what do the points in the non-neoplastic and benign samples represent if no mutations were found?

4\) The authors can claim that \"the presence of a mutation was highly informative for the presence of a cyst requiring surgery in the multivariate analysis, as no mutations were found in cysts not requiring surgery (P\<0.001)\" at the end of Results. The authors, however, should also acknowledge that this assay, in the current format, cannot completely rule out that the patient does not require surgery if the assay does not result in any detectable mutations. Other markers like CA125 did not provide much information, as there were many cysts not requiring surgery also had high levels of CA125 than those requiring surgery. The patients might still opt for surgery with a negative mutation finding.

5\) Introduction, paragraph two: the authors cite that 5% of patients in the PLCO screening study had malignancy, which is an interesting and important point; however, this screening practice with serial pelvic ultrasounds is not common practice. Does the author have a citation for the risk of malignancy in patients who are symptomatic who present with concerning features on ultrasound as this is a very different population than a screening population?

6\) Introduction, paragraph two: What is the citation for the 15% surgical complication rate? With laparoscopic surgery the complication rate for a USO should be far less than 15% and even \<15% in laparotomy.

7\) The authors address the possibility of using cyst fluid DNA analysis as part of a diagnostic algorithm. The pre-operative US findings for the 77 cases thus would be important to add to this work to better characterize the diagnostic utility. For example, were all of the benign cysts simple appearing and thus by convention a low pre-test probability for malignancy or did they have concerning US features. Including this as well as their pre-op HE4 or CA-125 with the molecular findings would strengthen this work.

Issues related to the clinical implications:

8\) The authors do address the major limitation of this study which is the clinical applicability. However, the understanding of when and how this technique could be utilized should be clarified as the current argument is too limited. The authors argue for the safety of US guided needle aspiration of ovarian cysts. While the points are reasonable, the author does not address the problem of upstaging a localized ovarian cancer. While recurrence rates may be the same, a stage IA tumor would not require adjuvant chemotherapy while a IC1 (surgical spill which would include a needle aspiration) would require chemotherapy associated with significant morbidity, impacts on fertility, while not necessarily changing survival or recurrence rate. This point needs to be included in the discussion as a limitation.

9\) Furthermore, this technique would require a change in standard of care, and thus would be important to define the exact population that this procedure would benefit. For example, all advanced stage tumors can be excluded as they are clearly malignant by pre-op evaluation. Patients with clearly benign tumors can be excluded- simple appearing cysts on US with normal CA-125. How many patients then are left to whom the pre-op diagnosis is unknown based on abnormal US findings and some elevation in CA-125? I can understand the utility as a confirmatory test for a benign lesion in a patient who by all other parameters appears benign based on the high specificity to rule out malignancy with genomic analysis, but the clinical role here as a screening test really should be flushed out further.

10.7554/eLife.15175.013

Author response

*Essential revisions:*

*Issues related to the study\'s methodology and interpretation:*

1\) Methodology needs more details: (i) which tools were used for sequence data alignment? (ii) which tools and what parameters were used for variant calling (including the minimum read count requirement or the minimum variant allele frequency)? (iii) what sequencing depth was achieved per sample? (iv) what was the sequence read quality cut-off used? (v) were variants manually reviewed? (vi) were variant calls limited to missense and nonsense mutations or were no silent mutations observed?

We have provided the requested details in the revised manuscript as follows:

i\) The sequences were aligned using custom scripts written in SQL and C\#.

ii\) High-quality reads were grouped into UID families. Only UID families with two or more members (reads) were considered. In order to be scored as a "supermutant", a mutation had to be present in \>90% of reads in each UID family and have a minimum variant allele frequency of 0.1%.

iii\) We have added a column in [Supplementary file 2](#SD2-data){ref-type="supplementary-material"} to indicate the sequencing depth (in terms of the number of UID families) for each sample or mutation identified. The median number of UID families for samples with sufficient DNA for analysis was 958 (\>1916 reads with the requirement of two or more reads per UID family).

iv\) The quality score cutoffs were 15 (base call accuracy of 97%) and 20 (base call accuracy of 99%) for the each of the fourteen UID bases and mutant base(s), respectively.

v\) The original data on the variants listed in [Supplementary file 2](#SD2-data){ref-type="supplementary-material"} were indeed manually reviewed. Moreover, each mutation was confirmed in through an independent PCR and sequencing experiment.

vi\) Silent mutations were observed but were not included in the variant calls because we could not be certain that they were functionally significant. Similarly, we excluded intronic mutations other than those at splice junctions for the same reason.

2\) Subsection "A multiplex PCR-based assay to identify tumor-specific mutations in cyst fluid samples": The 5 samples without sufficient DNA should not be included in the analysis. These cases should be excluded instead of included as negative because in clinical practice this would be uninterpretable and thus represents a failure of the technique. While this is small, 5/77 (6.5%) it still should be reported in this manner as low DNA alone, as the authors indicated, is not indicative of a benign cyst and 1 borderline tumor would have been missed with this technique.

We have revised the manuscript and excluded these five cases from further interpretation.

3\) In [Figure 2](#fig2){ref-type="fig"} what do the points in the non-neoplastic and benign samples represent if no mutations were found?

We thank the reviewers for pointing out this source of potential confusion. These points represented \"zero\" mutants, but because of the log scale, we included them on the x-axis, the lowest point possible in log-scale. In the revised [Figure 2](#fig2){ref-type="fig"}, we have removed the points in the non-neoplastic and benign samples to more clearly indicate the lack of mutations found in those samples.

4\) The authors can claim that \"the presence of a mutation was highly informative for the presence of a cyst requiring surgery in the multivariate analysis, as no mutations were found in cysts not requiring surgery (P\<0.001)\" at the end of Results. The authors, however, should also acknowledge that this assay, in the current format, cannot completely rule out that the patient does not require surgery if the assay does not result in any detectable mutations. Other markers like CA125 did not provide much information, as there were many cysts not requiring surgery also had high levels of CA125 than those requiring surgery. The patients might still opt for surgery with a negative mutation finding.

This is an important point and we have revised the Discussion to include the following statement:

"However, our assay in its current format cannot completely rule out malignancy because a fraction of early-stage cancer patients did not have detectable mutations in their cysts. Therefore, patients whose clinical and functional status allows them to undergo surgery and anesthesia might still choose to have a surgical procedure. On the other hand, a minimally invasive test that provides additional, orthogonal information to patients and surgeons could inform their decision about the advisability of surgery."

5\) Introduction, paragraph two: the authors cite that 5% of patients in the PLCO screening study had malignancy, which is an interesting and important point; however, this screening practice with serial pelvic ultrasounds is not common practice. Does the author have a citation for the risk of malignancy in patients who are symptomatic who present with concerning features on ultrasound as this is a very different population than a screening population?

Thanks for asking us to clarify this point. In the DOvE study of 1455 symptomatic women, 197 women had abnormal features on ultrasound. Of these 197 women, 8 cases (4%) of ovarian cancers were ultimately found (Gilbert L. et al. Lancet Oncol. 2012 Mar;13(3):285-91). We have added this reference to the Introduction.

*6) Introduction, paragraph two: What is the citation for the 15% surgical complication rate? With laparoscopic surgery the complication rate for a USO should be far less than 15% and even \<15% in laparotomy.*

In the revised version, we more specifically cite the study on the complication rate (Buys S. et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011 Jun 8;305(22):2295-303). This study reports that "of 3285 women with false-positive results, 1080 underwent surgical follow-up; of whom, 163 women experienced at least one serious complication (15%)."

7\) The authors address the possibility of using cyst fluid DNA analysis as part of a diagnostic algorithm. The pre-operative US findings for the 77 cases thus would be important to add to this work to better characterize the diagnostic utility. For example, were all of the benign cysts simple appearing and thus by convention a low pre-test probability for malignancy or did they have concerning US features. Including this as well as their pre-op HE4 or CA-125 with the molecular findings would strengthen this work.

Another important point which we appreciate you raising. All 77 patients had suspicious findings on ultrasound or CT scan in their ovarian cysts, which prompted their surgical removal. We have added this information to the revised manuscript, which as before also includes the pre-op HE4 and CA-125. However, the various imaging criteria used by the surgeons to decide whether to perform surgery were not standardized and changed over the course of the collection period of this study. Some used US (either IOTA or RMI), while others used CT. All we can state is that highly-trained gynecologic oncology surgeons thought each of these 77 patients had worrisome findings mandating surgery.

*Issues related to the clinical implications:*

8\) The authors do address the major limitation of this study which is the clinical applicability. However, the understanding of when and how this technique could be utilized should be clarified as the current argument is too limited. The authors argue for the safety of US guided needle aspiration of ovarian cysts. While the points are reasonable, the author does not address the problem of upstaging a localized ovarian cancer. While recurrence rates may be the same, a stage IA tumor would not require adjuvant chemotherapy while a IC1 (surgical spill which would include a needle aspiration) would require chemotherapy associated with significant morbidity, impacts on fertility, while not necessarily changing survival or recurrence rate. This point needs to be included in the discussion as a limitation.

We thank the reviewer for suggesting that we specifically address this point. We also realize that there is some skepticism towards the diagnostic utility and safety of ovarian cyst aspiration in the gynecological community. However we are not the first to encounter such skepticism when presenting a novel diagnostic approach. When colonoscopy was first introduced by Drs. William Wolff and Hiromi Shinya in 1969, it was perceived as both "unnecessary and unduly dangerous" (Wolff W. Am J Gastroenterol. 1989 Sep;84(9):1017-25). This skepticism only began to fade when it was demonstrated that the colonoscope could reveal changes not disclosed by conventional methods at the time. Over the next few decades, and only after many subsequent studies, was the scope's safety and clinical efficacy demonstrated. Analogously, we have introduced a sort of "molecular scope" for cystic lesions of the ovary that can reveal information unobtainable by conventional methods. As with all such proof-of-principle studies, its clinical safety and efficacy need to be validated in a larger prospective trial. Nevertheless, our data suggest that this new approach, in conjunction with current diagnostic methods, has the potential to improve the management of the vast number of women with ovarian cysts.

To more specifically address the point about Stage I patients, we have modified the revised manuscript to point out that one of the advantages of the approach is that it could lead to planning a less radical surgery in a Stage I patient with *BRAF* or *KRAS* mutation than in a Stage I patient with a *TP53* mutation. The less radical surgery would have a variety of beneficial effects, including maintenance of fertility if desired. On the other hand, we also acknowledge that, under current recommendations, a surgical spill could upstage a localized tumor (i.e. stage 1A to IC) and subject the patient to chemotherapy with its associated morbidity.

9\) Furthermore, this technique would require a change in standard of care, and thus would be important to define the exact population that this procedure would benefit. For example, all advanced stage tumors can be excluded as they are clearly malignant by pre-op evaluation. Patients with clearly benign tumors can be excluded- simple appearing cysts on US with normal CA-125. How many patients then are left to whom the pre-op diagnosis is unknown based on abnormal US findings and some elevation in CA-125? I can understand the utility as a confirmatory test for a benign lesion in a patient who by all other parameters appears benign based on the high specificity to rule out malignancy with genomic analysis, but the clinical role here as a screening test really should be flushed out further.

This is an important point that we agree is worthy of further clarification. We do not envision this test as a screening test -- only a diagnostic test for women whose diagnosis is doubtful on the basis of conventional clinical and radiologic criteria. The point noted above, i.e., sparing some women radical surgery when the genetic analysis of their cysts indicates that they have a *BRAF* or *KRAS* mutation, is one form of clinical utility. We agree with the reviewer that those with advanced stage tumors would not benefit from this sort of analysis. However, the diagnosis of earlier stage neoplasms is considerably more difficult. We have added the following information to the revised manuscript to make this point more clearly:

"This study was driven by the need for a biomarker that would help distinguish malignant ovarian tumors from benign lesions and thereby reduce the number of unnecessary surgeries. \[...\] Finally, the procedure can be performed minimally invasively in an outpatient setting. The goal of our test is not to replace clinical, radiologic, or sonographic evaluation but to augment them with molecular genetic markers."

[^1]: These authors contributed equally to this work.
